<DOC>
	<DOCNO>NCT01888484</DOCNO>
	<brief_summary>This open-label phase III study 12-week wash-in/wash-out period follow 12-month efficacy period . The main goal study assess efficacy octanorm prevent serious bacterial infection ( SBI ) compare historical control data evaluate pharmacokinetic ( PK ) characteristic octanorm .</brief_summary>
	<brief_title>Study Octanorm Subcutaneous IG Patients With PID</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Age least 2 year include 75 year . 2 . Confirmed diagnosis PI define ESID PAGID require immunoglobulin replacement therapy due hypogammaglobulinaemia agammaglobulinaemia . The exact type PI record . 3 . Patients least 6 infusion regular treatment IVIG , minimum last 2 month product prior enter study . Constant IVIG dose 200 800 mg/kg body weight ( ±20 % mean dose last 6 infusion ) . 4 . Availability IgG trough level 2 previous IVIG infusion enrollment , maintenance great equal 5.0 g/L trough level 2 previous infusion . 5 . Negative result pregnancy test ( HCGbased assay urine ) woman childbearing potential use reliable method contraception duration study . 6 . For adult patient : freely give write informed consent . For minor patient : freely give write informed consent parents/legal guardian write informed assent child/adolescent accordance applicable regulatory requirement . 7 . Willingness comply aspect protocol , include blood sampling , duration study . 1 . Acute infection require intravenous antibiotic treatment within 2 week prior screen period . 2 . Known history adverse reaction IgA product . 3 . Patients body mass index ≥40 kg/m2 . 4 . Exposure blood blood product plasma derivative , IVIG treatment PID , within past 3 month prior first infusion octanorm . 5 . Ongoing history hypersensitivity persistent reaction blood plasma derive product , component investigational product ( Polysorbate 80 ) . 6 . Requirement routine premedication IgG administration . 7 . History malignancy lymphoid cell immunodeficiency lymphoma . 8 . Severe liver function impairment ( ALAT 3 time upper limit normal ) . 9 . Known proteinlosing enteropathy proteinuria . 10 . Presence renal function impairment ( creatinine great 120 uM/L ) , creatinine great 1.35 mg/dL ) , predisposition acute renal failure ( e.g. , degree preexist renal insufficiency routine treatment know nephritic drug ) . 11 . Treatment oral parenteral steroid great equal 30 day give intermittently bolus daily dos great equal 0.15 mg/kg . 12 . Treatment immunosuppressive immunomodulatory drug . 13 . Live viral vaccination ( measles , rubella , mumps varicella ) within last 2 month prior first infusion octanorm . 14 . Treatment investigational medicinal product within 3 month prior first infusion octanorm . 15 . Presence condition , likely interfere evaluation study medication satisfactory conduct trial . 16 . Known suspected abuse alcohol , drug , psychotropic agent chemical within past 12 month prior first infusion octanorm . 17 . Known suspected HIV , HCV , HBV infection . 18 . Pregnant nursing woman plan pregnancy course study 19. . .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PID</keyword>
</DOC>